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Purpose: To evaluate the pharmacodynamic effect of N-acetylcysteine (NAC) in mild systemic lupus 
erythematosus (SLE) patients in order to implement NAC as adjunctive therapy in SLE population. 
Methods: Forty mild SLE patients were randomly allocated to receive 1800 mg of NAC with SLE 
standard therapy or receive standard therapy alone.  Follow up was performed at 2 weeks, then every 
month up to 6 months.  Glutathione GSH and malondialdehyde (MDA), a lipid peroxidation product in 
plasma, were measured at each visit; clinical symptoms were also evaluated.  
Results: Supplementation with 1800 mg of NAC did not significantly (p > 0.05) affect GSH level; 
however, MDA level was significantly (p < 0.05) decreased and the number of patients who could tapper 
prednisolone dosage was higher in the NAC group than in the control group.   
Conclusion: Administration of NAC may be beneficial in mild SLE patients in terms of decreasing lipid 
peroxidation. However, this conclusion does not apply to the effect of NAC at different dosages for 
moderate and severe SLE. Further studies are required in this regard 
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INTRODUCTION 
 
N-acetylcysteine (NAC) is an old nutrient 
which is indicated as a mucolytic agent and 
antidote for paracetamol intoxication.  It is a 
glutahione (GSH) precursor and is 
deacetylated to cysteine (Cys), amino acid 
which is a substrate of GSH biosynthesis 
enzyme.  GSH is an important biomolecule 
which has high antioxidant activity[1]. There 
have been studies of  its role in many 
diseases such as cardiovascular diseases, 
diabetes,  HIV infection  and  cancer [1-3]. 
GSH may be a marker of longevity [3-5]. 
 
In systemic lupus erythematosus (SLE), an 
imbalance of oxidative status has been found 
in some studies. Additionally, enhancement 
of lipid peroxidation and deficiency of 
antioxidant status were observed [6-12]. In 
deficiency of antioxidative status in SLE 
patients, supplementation with a glutathione 
precursor has been used as a strategy for the 
reduction of active symptoms in SLE patients.  
Therefore, the aim of this study was to 
evaluate the pharmacodynamic effect and 
safety profile of NAC in mild SLE patients on 
standard therapy.   
  




Following approved by the Ethics Committee 
of Ramathibodi [13], 40 SLE patients were 
randomly assigned to 2 groups (control and 
NAC administration) and an attempt was 
made to match them with age, sex and 
medication.  The demographic data for these 
2 groups was recorded.  
 
The inclusion criteria were (a) males or 
females aged > 18 years who were 
diagnosed with SLE according to the 
American College of Rheumatology (ACR) 
criteria and in whom the condition was mild 
according to the definition; (b) patients who 
received standard treatment for mild SLE; 
and (c) patients who were willing to be 
included in the study and signed the informed 
consent form. Patients were excluded if they 
(a) were poorly compliant with drug regimens 
by interview  or any evidence (such as 
unused medications); (b) were pregnant or 
lactating; (c) had hypersensitivity or 
intolerance to NAC; (d) had infectious or liver 
diseases; and (e) were considered by their 





One group received standard therapy and 
another group received 600 mg of N- 
acetylcystiene [NAC] thrice daily. The 
effectiveness of this dosage in avelolitis 
patients who received co-administration with 
maintenance immunosuppressives is well 
known. 
 
Study monitoring and pharmacodynamic 
evaluation 
 
Five milliliters of blood samples was collected 
at each visit. Blood samples were drawn and 
immediately chilled in iced box.  Plasma was 
separated by centrifugation at 2 °C and 3000 
rpm for 10 min.  These specimens were then 
kept at -20°C and analyzed within 2 weeks.  
 
Glutathione analysis was performed using 
glutathione assay kit (Bioassay system Inc, 
California, USA). Malondialdehyde (MDA), a 
lipid peroxidation product, was measured 
according to the method of Yagi [14], using a 
microplate reader (Victor
2
  Pergin Almer Inc, 
CA, USA) as a detector.  
 
The demographic data and baseline 
characteristics of both groups were recorded. 
The following pharmacodynamic parameters 
at baseline, 2 weeks, then every month up to 
6 months were measured: plasma glutathione 
(GSH), plasma MDA. In addition, the number 
of patients who could tapper prednisolone 
were recorded; follow-up was set at 2 weeks, 
then monthly up to 6 months.  SLE activity 
index SLEDAI scores at baseline and 6 
months were also recorded for evaluation of 
clinical outcomes. The clinical outcomes and 
safety profile of NAC with standard therapy 
were also evaluated.  
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Data analysis 
 
Both dependent and independent Student t-
tests were used to test differences in GSH 
and MDA concentration of the 2 groups at 
base line and 6 months in order to determine 
the efficacy of NAC. Chi-square test was 
used to compare the number of SLE patients 
in the 2 groups who could tapper 
prednisolone. Differences were considered 




The demographic, medication and laboratory 
data for the SLE patients are listed in Table 
1. Patients in the 2 groups had almost similar 
characteristics, except platelet and ALT. 
 
The effect of NAC on GSH, MDA and 
SLEDAI score are shown in Table 2. The 
analytical methods for GSH and MDA were 
validated and they gave coefficient of 
variation (CV) of < 10 % for intra-day and 
inter-day precision, and recovery was > 90 %. 
Correlation coefficient was 0.99. 
 
There was a significant difference (p < 0.05) 
in the plasma GSH levels of the 2 groups but 
the difference was not significant (p < 0.05) in 
the case of MDA levels. In addition, there 
was a statistical difference in proportion of 
SLE patients who could tapper prednisolone. 
All the patients in the NAC group could 
tapper prednisolone while only 13 patients in 
the control group could reduce prednisolone 
dose. Chi-square test data are shown in 
Tables 3 and 4, respectively. Both 2 groups 
could significantly decrease in prednisolone 
dose based on comparison of prednisolone 
dose at baseline and 6 months. 
 
However, when subgroup analysis according 
to SLEDAI score was performed, it found that 
only NAC groups showed a significant 
decrease in prednisolone dosing at 6 months, 
as indicated in Table 5.  However, this 
occurred was only among those in NAC 
group whose SLEDAI score was < 4 and ≥ 4, 
as shown in Table 5 (p < 0.005).    
 
Table 1:  Dermographics, medication and laboratory characteristic of SLE patients  
 
 
Characteristics  Control (n=20) NAC group (n=20) p-value 
Age (year, mean + SD ) 36 + 8.5 35 + 0.1 0.72 
Sex Female Female 1.00 
Duration of SLE  (year, mean + SD) 10.0+ 6.9 9.0+ 6.4 0.604 
Drugs       
Predinsolone   18 17 0.500 
Hydroxychloroquine 13 17 0.273 
Azathioprine 7 7 0.629 
NSAIDs 4 4 0.653 
Prednisolone +hydroxychloroquine 11 15 1.00 
Prednisolone +azathioprine 7 5 1.00 
Prednisolone + hydroxychloroquine +Azathioprine 4 3 1.00 
Laboratory data       
Hemoglobin  (mg/dL, mean + SD) 12.0 + 0.9 12.3 +  1.5 0.426 
Hematocrit (mg/dL, mean + SD) 35.5+ 3.0 36.5+ 0.4 0.437 
SLEDAI score 3 2 0.426 
WBC (cell/m3 , mean + SD)  5776+ 2156 6713+ 3957 0.269 
Plt  (cell/m3 , mean + SD) 248055  +  92203 314900+  81721 0.020* 
ESR (h-1 ,  mean + SD) 34.2 + 22.8 33.1 + 24.9 0.851 
SCr  (mg/dL, mean + SD) 0.786 + 0.335 0.760+ 0.210 0.891 
AST ((IU. , mean + SD) 36.7 + 1.2  47.3 + 27.6 0.347 
ALT ((IU. , mean + SD) 87.8 + 38,4 36.6 + 18.4 0.039* 
MDA (µM/L, mean + SEM ) 0.362 + 0.042 0.417 + 0.050 0.479 
GSH (µM/L, mean + SEM) 574.6 + 84.0 673.5 + 70.8 0.401 
*Significant difference at p < 0.05; Plt = platelet. ESR =  erythrocyte sedimentation rate, Scr = serum creatinine, AST = 
aspartate trasferase, ALT =  alanine trasferase, MDA = malondialdehyde, GSH=glutathione 
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Table 2: Effect of N-acetylcysteine on oxidative status parameters (GSH and MDA) and  SLE activity 










MDA (µM) Control 
NAC 
0.362 + 0.042 
0.417 + 0.050 
  0.371 + 0.042 
0.291 + 0.033 
0.875 
0.023* 
GSH (µM) Control 
NAC 
575 + 84 
673 + 71 
839 + 162 











* Statistically significantdifference at p < 0.05 
 
Table 3:  Number of SLE patients who could tapper prednisolone 
 
Prednislone tapper Group* 
 Control NAC 
Total 
No 7 0 7 
Yes 13 20 33 
Total 20 20 40 
* p = 0.008 
 
Table 4: Chi-square test of prednisolone tappering in control versus NAC group 
 






Pearson Chi-Square 8.485 1 .004   
Continuity Correction 6.234 1 .013   
Likelihood Ratio 11.200 1 .001   
Fisher's Exact Test    .008* .004* 
Linear-by-Linear 
Association 
8.273 1 .004   
No. of valid cases 40     
Note: Data computed only for a 2x2 table; two cells (50 %) showed expected count < 5, the minimum 
expected count being 3.50; * Statistically significant  
Table 5:  Effect of NAC on prednisolone dose in 6 months  
 
Parameter 
(mean + SEM) 
Group N Baseline 6 months p value 
Prednisolone dose (mg) for  





130.8 + 31.1 
118.4 + 25.5 
53.3 + 10.0 
47.5 + 11.4 
0.012* 
0.002* 
Prednisolone dose (mg) of 
subjects who had SLEDAI >  





172.2 + 68.4 
150.6 + 70.8 
68.8 + 29.4 
 59.2 + 37.2 
0.124 
0.014* 
Prednisolone dose (mg) of 
subjects who had SLEDAI < 





141.6 + 42.7 
97.50 + 17.57 
51.3 + 15.5 





Clinical outcomes and adverse effects of 
NAC 
 
Based on random interview of patients who 
received NAC, four patients said they felt 
better, fresher, and had better skin 
appearance.  In addition, an interview with 
one physician who took care of the patients 
who received NAC showed that the clinical 
outcomes of the patients improved, as 
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indicated,by laboratory test results, improved 
clinical symptoms such as decreased hair 
loss, as well as absence of new rash, fatigue 
and joint pain. However, during the study, 4 
patients were withdrawn and and substituted 
with SLE patients in the NAC group. Among 
them, one patient experienced shortness of 
breath; another developed a rash and two 
experienced headache. These symptoms, 
however, disappeared when the drug was 




Based on the results obtained, administration 
of 1800 mg NAC as adjunctive therapy did 
not produce a significant change in GSH 
level, while the MDA level of NAC group was 
significantly lower than in the control group 
during the six months of therapy.   This result 
was similar to the phase I study on the effect 
of NAC as a chemopreventive in patients who 
suffered from malignancy [15].   In that study, 
there was no correlation between NAC 
concentration and change in GSH in 
peripheral blood lymphocyte; furthermore, the 
effect of NAC  as  a glutathione precursor 
was prolonged only for a short time and this 
positive effect occurred only in some patients 
[16].   This may be due to the pro-oxidant  
effect of NAC which  was found the in vitro 
study [17].  High doses of NAC might have 
caused the increased formation of free 
radicals and thus resulted in lower GSH level 
than in the control group.  Significant anti-
oxidant effect [18-20] was also found by 
lowering MDA levels  during the 6 months of 
therapy.   
 
Consideration of the mechanism of action of 
NAC which may provide an insight into the 
understanding of the results obtained. 
Although deacetylation of NAC releases 
cysteine which is the primary agent for 
glutathione synthesis, the synthetic process 
of GSH does not only depend on cysteine. It 
also requires two other amino acids - glycine 
and glutamine. Therefore, increased GSH 
levels resulting from NAC therapy sometimes 
does not rise sharply if glycine and glutamine 
levels are inadequate. In contrast, MDA 
synthesis originates from lipid peroxidation 
and is not dependent on other agents. 
Therefore, lipid peroxidation effect, which is 
inhibited by NAC, increased markedly, 
leading to a significant decrease in plasma 
MDA level.  Polymorphism of glutathione 
synthase enzyme and SLE has also been 
established [21-23]. 
 
All the patients in NAC group could tapper 
prednisolone while only 13 patients in the 
control group were able to do so. in this 
regard, the difference between the two 
groups was statistically significant different (p 
= 0.008).   
 
Limitations of study 
 
This study had a couple of limitations, the first 
being that only one dose of NAC was 
administered, and therefore, the results are 
based on administration at one dose level, 
i.e., 1800 mg.  Further studies are required to 
determine the outcome at other dose levels 
of NAC. Another limitation has to do with the 
level of severity of the SLE patients since 
only mild SLE patients were recruited. 
Expansion of the study to moderate or severe 
SLE patients could have possibly resulted in 




Administration of 1800 mg NAC may be 
beneficial to SLE patients who who suffer 
minor symptoms and are able to tapper 
prednisolone which may cause many side 
effect.  Based on these results, it would be 
necessary to study the effect of N-
acetylcystiene in moderate and severe SLE 
cases as this would facilitate the 
implementation of NAC therapy for moderate 
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